Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation
NCT07483385Recruiting
- Sponsor
- General Hospital of Western Theater Command of PLA
- Start
- Jan 2026
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of lusutrombopag in Thrombocytopenia, sponsored by General Hospital of Western Theater Command of PLA. Primary endpoint: Transplantation + 21-day platelet accumulation engraftment rate. Started Jan 2026; status: recruiting.
02
Drugs
lusutrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT07483385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07483385.